CDSCO has granted permission to CMC, Vellore, to conduct phase-IV study with Covishield and Covaxin to compare immunogenicity of mixed vaccine regimen, and to Bharat Biotech for phase-II clinical trial to evaluate the immunogenicity and safety of Covaxin with BBV154, Bharati Pravin Pawar, Minister of State for Health, said in Rajya Sabha yesterday
The National Technical Advisory Group on Immunisation (NTAGI) needs adequate scientific data to make a recommendation on mixing of COVID-19 vaccines, the government said yesterday.
The Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore, to conduct phase-IV study with Covishield and Covaxin to compare immunogenicity of mixed vaccine regimen and to Bharat Biotech for phase-II clinical trial to evaluate the immunogenicity and safety of Covaxin with BBV154 (adenoviral intra-nasal COVID-19 vaccine), Bharati Pravin Pawar, Minister of State for Health, said.
“Adequate scientific data is required for NTAGI to make a recommendation on mixing of COVID-19 vaccines, at present, this information is not available,” Pawar said in a written reply in the Rajya Sabha.
She was responding to question on whether the government is considering mixing of COVID-19 vaccines based on heterologous strategies conducted earlier for other diseases, to induce combined antibody and cell-mediated immune response resulting in stronger and long-lasting immunity, and, if any study has been undertaken in this regard.
- Advertisement -